Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 5/20 | 0.58 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.50 |
| ▸ | PTPRA | P18433 | 1/20 | 0.49 |
| ▸ | GRIA1 | P42261 | 6/20 | 0.47 |
| ▸ | CHRND | Q07001 | 5/20 | 0.47 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.47 |
| ▸ | CHRNG | P07510 | 1/20 | 0.47 |
| ▸ | CHRNB1 | P11230 | 1/20 | 0.47 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | PLAU | P00749 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.46 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7065637 | 0.84 | PTPN1 (0.51) | PTPN1PTPN2PTPRAGRIA1CHRND | |
| SCHEMBL7065966 | 0.84 | PTPN1 (0.55) | PTPN1PTPN2PTPRAGRIA1PLG | |
| SCHEMBL8914296 | 0.78 | DPP7 (0.55) | GRIA1 | |
| SCHEMBL7064468 | 0.77 | PTPN1 (0.61) | PTPN1PTPRAGRIA1PLGPRSS1 | |
| SCHEMBL6572379 | 0.77 | PTPN1 (0.54) | PTPN1PTPN2PTPRAPLGPRSS1 | |
| SCHEMBL6918308 | 0.76 | PTPN1 (0.69) | PTPN1GRIA1CHRNDCHRNA1CHRNG | |
| SCHEMBL13073722 | 0.73 | KMT2A (0.53) | PTPN1 | |
| SCHEMBL11207112 | 0.71 | GRIA1 (0.59) | PTPN1PTPRAGRIA1CHRNDCHRNA1 | |
| SCHEMBL8713012 | 0.71 | ITGB3 (0.67) | — | |
| SCHEMBL8713009 | 0.71 | ITGB3 (0.67) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1313696-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2003-05-28 | — | — | EP | disclosed |
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | ABBOTT LABORATORIES | 2002-03-21 | — | — | US | disclosed |
| WO-2002018323-A2 | AMINO(OXO)ACETIC ACID PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ABBOTT LABORATORIES (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020035137-A1 | Amino (oxo) acetic acid protein tyrosine phosphatase inhibitors | PPM1A, PTPRO, PTP4A1 | PTPN1 10/4885PTPN2 29/4885PTPRA 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.